Dr. Patrick Garidel, Boehringer Ingelheim - Qepler Summits And Conferences

Dr. Patrick Garidel

Head of Process, Purification and Pharma Development, Biopharma
Boehringer Ingelheim
Hamburg, Germany
 Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.

Dr. Patrick Garidel is currently employed as associate director protein science at Boehringer Ingelheim Pharma GmbH & Co. KG.

His activities are focused on the development biologics from the downstream process to drug product (liquid and solid formulations, freeze-drying).

His expertise covers: development of drug delivery system and formulations, packaging/devices, process development, bio-analytic, and protein purification.

He is responsible for the establishment of innovative platform technologies for e.g. powder inhalation, gene therapy, in silico based predictive tools for molecule properties, and particle analytics.

Additionally, he is interested in the development of new concepts and strategies for protein purification, stabilisation, delivery and protein/ colloid chemistry in general.

Patrick Garidel studied chemistry and biotechnology at the University of Kaiserslautern and pharmaceutical sciences at the University of Strasbourg. He has a PhD in biophysics. During his academic career, he took over various post doc positions at the Institute for Pharmaceutical Technology and Biopharmacy, physical chemistry at the Martin Luther University Halle/ Wittenberg, DESY, Rutgers University and Hospital for Special Surgery.

Related Sessions:

2nd Annual Pharmaceutical
Lyophilization Summit 2020

Discuss best practices in tech & regulatory updates, process, formulation, testing, monitoring, new products development.
  • 12 Feb 2020
  • Berlin, DE
  • Pharma
Day 1: Wednesday, 12 February 2020
CASE STUDY: Lyophilization and Biologics
View Details